Cytomegalovirus disease among donor-positive/ recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis

Journal of Heart and Lung Transplantation

Volumn 29, Issue 9, 2010, Pages 1014-1020

  Mitsani, Dimitra ^a   Nguyen, M Hong ^a   Kwak, Eun J ^a   Silveira, Fernanda P ^a   Vadnerkar, Aniket ^a   Pilewski, Joseph ^a   Crespo, Maria ^a   Toyoda, Yoshiya ^b   Bermudez, Christian ^b   Clancy, Cornelius J ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; cytomegalovirus; Lung transplantation; Risk factors; Valganciclovir

Indexed keywords

ALEMTUZUMAB; GANCICLOVIR; VALGANCICLOVIR; VORICONAZOLE; ANTIVIRUS AGENT; CANCER ANTIBODY; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; ASYMPTOMATIC INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; VIREMIA; ACUTE DISEASE; ADOLESCENT; AGED; DISEASE TRANSMISSION; DONOR; GRAFT REJECTION; MIDDLE AGED; REOPERATION; STATISTICS; SURVIVOR; TIME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PYRIMIDINES; REOPERATION; RETROSPECTIVE STUDIES; SURVIVORS; TIME FACTORS; TISSUE DONORS; TRIAZOLES;

EID: 78650526429     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2010.04.022     Document Type: Article

References (47)

1. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017-23. (Pubitemid 23093832)
2. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001;3:128-37. (Pubitemid 32756695)
3. Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001;3(suppl 2):49-56. (Pubitemid 34073657)
4. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991;10:638-44; discussion 45-6.
5. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992;146:1419-25.
6. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994;150:146-52. (Pubitemid 24209951)
7. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999;116:1265-72. (Pubitemid 29535978)
8. Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998;113:924-32. (Pubitemid 28216434)
9. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996;15:881-7. (Pubitemid 26320212)
10. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999;67:315-20. (Pubitemid 29066362)
11. Weill D, Lock BJ, Wewers DL, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003;3:492-6. (Pubitemid 36560103)
12. Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int 1999;12:254-60. (Pubitemid 29423663)
13. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008;27:875-81.
14. Brumble LM, Milstone AP, Loyd JE, et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest 2002;121:407-14. (Pubitemid 34132976)
15. Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev 2000:CD001320.
16. Maurer JR, Snell G, deHoyos A, Kesten S, Winton T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc 1993;25:1434-5. (Pubitemid 23079051)
17. Hertz MI, Jordan C, Savik SK, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998;17:913-20. (Pubitemid 28440855)
18. Kelly J, Hurley D, Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000;19:355-9. (Pubitemid 30211658)
19. Bhorade SM, Sandesara C, Garrity ER, et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001;20:928-34. (Pubitemid 32824137)
20. Monforte V, Roman A, Gavalda J, et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 2005;37:4039-42. (Pubitemid 43015248)
21. Cochrane AB. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. Am J Health Syst Pharm 2006;63:S17-21. (Pubitemid 44477467)
22. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20. (Pubitemid 38523584)
23. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635-42. (Pubitemid 39312297)
24. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005;5:1462-8. (Pubitemid 40839439)
25. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009;28:670-5.
26. Monforte V, Lopez C, Santos F, et al. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transplant 2009;9:1134-41.
27. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831-9. (Pubitemid 351417183)
28. Cytomegalovirus. American Journal of Transplantation 2004;4:51-8.
29. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009;9:S78-86.
30. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a singlecenter, retrospective analysis. Pharmacotherapy 2004;24:1323-30. (Pubitemid 39304996)
31. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005;19:273-8. (Pubitemid 40424902)
32. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in highrisk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003;3:731-5. (Pubitemid 36745246)
33. Perrottet N, Csajka C, Pascual M, et al. Population pharmacokinetics of ganciclovir in solid organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 2009;53:3017-23.
34. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44:495-507. (Pubitemid 40733734)
35. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79:1477-83. (Pubitemid 40847577)
36. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidencebased reassessment of safety and efficacy. PLoS One 2009;4:e5512.
37. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 2007;26:1019-24. (Pubitemid 47500146)
38. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002;185:20-7. (Pubitemid 34043012)
39. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45:439-47. (Pubitemid 47204459)
40. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant 2007;26:1286-92. (Pubitemid 350256987)
41. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4-13; discussion 14.
42. Johanssson I, Martensson G, Andersson R. Cytomegalovirus and longterm outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis 2010; 42:129 -36.
43. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996;15:1200-8. (Pubitemid 26428395)
44. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009;87:719-25.
45. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004;170:1120-3. (Pubitemid 39488626)
46. Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006;81:1415-20. (Pubitemid 43847152)
47. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63. (Pubitemid 34627201)